Actively Recruiting
A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients
Led by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Updated on 2024-07-30
235
Participants Needed
1
Research Sites
53 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study includes two parts, part A is for non-squamous NSCLC and part B is for squamous NSCLC.
CONDITIONS
Official Title
A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Males and/or females over age 18
- Histologically and/or cytologically confirmed advanced or metastatic NSCLC
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Expected survival of 3 months or longer
- Signed informed consent form
You will not qualify if you...
- Known uncontrolled or symptomatic central nervous system metastatic disease
- Adverse events greater than grade 1 (except alopecia and fatigue) from any prior anticancer therapy
- Inadequate organ or bone marrow function
- Pregnant or breastfeeding women
- Known allergies, hypersensitivity, or intolerance to SSGJ-707
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institute of The Hunan Cancer Hospital
Changsha, China
Actively Recruiting
Research Team
L
Lin Wu, MD, Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
10
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here